MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.240
-0.120
-5.08%
Opening 13:54 03/03 EST
OPEN
2.380
PREV CLOSE
2.360
HIGH
2.390
LOW
2.210
VOLUME
2.59M
TURNOVER
--
52 WEEK HIGH
3.790
52 WEEK LOW
0.9895
MARKET CAP
220.70M
P/E (TTM)
-2.1603
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody b...
TipRanks.com · 6d ago
Top Penny Stocks To Buy Now? 4 To Watch Today
Feb 24, 2021 (Penny Stocks via COMTEX) -- Monday, February 8th, marked a new week for penny stocks. Overall, the stock market saw a large bullish jump...
Penny Stocks · 6d ago
Making A List Of Penny Stocks To Buy This Week? Analysts Like These 5
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Penny Stocks To Buy According To These 4 Analysts I know it's the weekend of the Big Game, and you may be...
Penny Stocks · 6d ago
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference...
GlobeNewswire · 02/22 12:30
H.C. Wainwright Remains a Buy on Abeona Therapeutics (ABEO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics (ABEO) today and set a price target of $8.00. The company's shares
SmarterAnalyst · 02/16 11:26
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium(TM) Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear ...
GlobeNewswire · 02/13 02:29
Abeona posts data from two early-stage rare lysosomal storage disease studies
Abeona Therapeutics ([[ABEO]] -4.8%) announces new data from two ongoing Phase 1/2 clinical trials of its AAV-based gene therapies ABO-102 and ABO-101 in rare lysosomal storage diseases MPS IIIA and MPS IIIB, respectively.The
Seekingalpha · 02/12 17:12
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeonas ABO-102 Gene Therapy
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear ...
GlobeNewswire · 02/12 16:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABEO. Analyze the recent business situations of Abeona through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABEO stock price target is 5.67 with a high estimate of 8.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 159
Institutional Holdings: 39.17M
% Owned: 39.75%
Shares Outstanding: 98.53M
TypeInstitutionsShares
Increased
29
7.30M
New
30
-6.39M
Decreased
13
4.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.68%
Pharmaceuticals & Medical Research
-1.59%
Key Executives
Chief Financial Officer/Chief Accounting Officer/Vice President
Edward Carr
Chief Operating Officer
Michael Amoroso
Director
Christine Silverstein
Chief Financial Officer/IR Contact Officer
Christine Berni-Silverstein
Independent Director
Paul Mann
Independent Director
Todd Wider
Other
Max Colao
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.